Clinical trialPhase 1 / Phase 2Terminated
Study to Assess AFM24 in Combination With Atezolizumab in Selected Advanced/Metastatic EGFR-expressing Cancers
A Phase 1/2a Open Label, Multicenter Study to Assess the Safety, Tolerability, Pharmacokinetics, and Efficacy of AFM24 in Combination With Atezolizumab in Patients With Selected Advanced/Metastatic EGFR-expressing Cancers
- Outcome
- Stopped early. Results posted; no analysis attachedThe trial was prematurely discontinued due to the financial situation of the sponsor and not for safety or efficacy reasons. (Business decision)
- Phase
- Phase 1 / Phase 2
- Status
- Terminated
- Study type
- Interventional
- Start
- 19 November 2021
- Ended
- 11 June 2025
- Enrollment
- 112 participants
- Sites
- 16
- Primary outcomes
- Phase 1: Incidence of Dose Limiting Toxicities (DLTs) During Cycle 1; Phase 2a: Overall Response Rate (Complete Response [CR] or Partial Response [PR])
- Sponsor type
- Industry
- Results posted
- 20 August 2025
- Last update
- 20 August 2025
These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.
Results
- Primary endpoint
- Results posted; no analysis attachedAs posted on ClinicalTrials.gov ↗, registry record of 20 August 2025
- DLT/MTD
- Phase 1: Incidence of Dose Limiting Toxicities (DLTs) During Cycle 1Phase 1 - Cohort 1 - AFM24 160 mg + Atezolizumab 840 mg: 0 of 4Phase 1 - Cohort 2 - AFM24 480 mg + Atezolizumab 840 mg: 1 of 6Values: ParticipantsTime frame: During cycle 1 (each cycle has 28 days)No analysis posted for this outcome (outcome 1)
- ORR
- Phase 2a: Overall Response Rate (Complete Response [CR] or Partial Response [PR])Phase 2 - Coh. EXP-1 (EGFR-WT NSCLC) - AFM24 480 mg + Atezolizumab 840 mg: 8 of 43Phase 2 - Coh. EXP-2 (Gastric or GEJ Adenocarcinoma) - AFM24 480 mg + Atezolizumab 840 mg: 1 of 12Phase 2 - Coh. EXP-3 (Hepatocellular,Hepatobiliary,Pancreatic) - AFM24 480 mg + Atezolizumab 840 mg: 1 of 11Phase 2 - Coh. EXP-4 (EGFR Kinase Domain Mutation NSCLC) - AFM24 480 mg + Atezolizumab 840 mg: 4 of 28Values: ParticipantsTime frame: Tumor assessments were conducted during last week of cycle 2, 4, 6, 8, 10, 12 and every 3 cycles thereafter (each cycle has 28 days), up to approximately 97 weeks.No analysis posted for this outcome (outcome 2)
- Participants
- Phase 1 - Cohort 1 - AFM24 160 mg + Atezolizumab 840 mg: 4 started, 0 completedPhase 1 - Cohort 2 - AFM24 480 mg + Atezolizumab 840 mg: 6 started, 0 completedPhase 2 - Coh. EXP-1 (EGFR-WT NSCLC) - AFM24 480 mg + Atezolizumab 840 mg: 49 started, 0 completedPhase 2 - Coh. EXP-2 (Gastric or GEJ Adenocarcinoma) - AFM24 480 mg + Atezolizumab 840 mg: 12 started, 0 completedPhase 2 - Coh. EXP-3 (Hepatocellular,Hepatobiliary,Pancreatic) - AFM24 480 mg + Atezolizumab 840 mg: 11 started, 0 completedPhase 2 - Coh. EXP-4 (EGFR Kinase Domain Mutation NSCLC) - AFM24 480 mg + Atezolizumab 840 mg: 30 started, 0 completed
- Serious adverse events
- Phase 1 - Cohort 1 - AFM24 160 mg + Atezolizumab 840 mg: 2 of 4Phase 1 - Cohort 2 - AFM24 480 mg + Atezolizumab 840 mg: 3 of 6Phase 2 - Coh. EXP-1 (EGFR-WT NSCLC) - AFM24 480 mg + Atezolizumab 840 mg: 30 of 49Phase 2 - Coh. EXP-2 (Gastric or GEJ Adenocarcinoma) - AFM24 480 mg + Atezolizumab 840 mg: 6 of 12Phase 2 - Coh. EXP-3 (Hepatocellular,Hepatobiliary,Pancreatic) - AFM24 480 mg + Atezolizumab 840 mg: 7 of 11Phase 2 - Coh. EXP-4 (EGFR Kinase Domain Mutation NSCLC) - AFM24 480 mg + Atezolizumab 840 mg: 15 of 30Participants with at least one serious adverse event, of those at risk, as posted
12 secondary outcomes, the first 8 shown
- Incidence of Patients With TEAEs
- Phase 1 - Cohort 1 - AFM24 160 mg + Ate… 4/4; Phase 1 - Cohort 2 - AFM24 480 mg + Ate… 6/6; Phase 2 - Coh. EXP-1 (EGFR-WT NSCLC) -… 49/49; Phase 2 - Coh. EXP-2 (Gastric or GEJ Ad… 11/12; Phase 2 - Coh. EXP-3 (Hepatocellular,He… 11/11; Phase 2 - Coh. EXP-4 (EGFR Kinase Domai… 30/30 [Participants]
- Incidence of Patients With SAEs
- Phase 1 - Cohort 1 - AFM24 160 mg + Ate… 2/4; Phase 1 - Cohort 2 - AFM24 480 mg + Ate… 3/6; Phase 2 - Coh. EXP-1 (EGFR-WT NSCLC) -… 30/49; Phase 2 - Coh. EXP-2 (Gastric or GEJ Ad… 6/12; Phase 2 - Coh. EXP-3 (Hepatocellular,He… 7/11; Phase 2 - Coh. EXP-4 (EGFR Kinase Domai… 15/30 [Participants]
- Pharmacokinetics (PK) of AFM24
- Phase 1 - Cohort 1 - AFM24 160 mg + Ate… 73700 (25400), n=3; Phase 1 - Cohort 2 - AFM24 480 mg + Ate… 269000 (61400), n=4; Phase 2 - Coh. EXP-1 (EGFR-WT NSCLC) -… 207000 (78100), n=35; Phase 2 - Coh. EXP-2 (Gastric or GEJ Ad… 207000 (73400), n=11; Phase 2 - Coh. EXP-3 (Hepatocellular,He… 175000 (77200), n=8; Phase 2 - Coh. EXP-4 (EGFR Kinase Domai… 250000 (106000), n=20 [mean ng/mL, Standard Deviation]
- Pharmacokinetics (PK) of AFM24
- Phase 1 - Cohort 1 - AFM24 160 mg + Ate… 16700 (12500), n=3; Phase 1 - Cohort 2 - AFM24 480 mg + Ate… 105000 (37200), n=4; Phase 2 - Coh. EXP-1 (EGFR-WT NSCLC) -… 56300 (48500), n=36; Phase 2 - Coh. EXP-2 (Gastric or GEJ Ad… 73700 (40900), n=12; Phase 2 - Coh. EXP-3 (Hepatocellular,He… 71900 (62500), n=7; Phase 2 - Coh. EXP-4 (EGFR Kinase Domai… 93700 (51600), n=19 [mean ng/mL, Standard Deviation]
- Pharmacokinetics (PK) of AFM24
- Phase 1 - Cohort 1 - AFM24 160 mg + Ate… 5760 (919), n=3; Phase 1 - Cohort 2 - AFM24 480 mg + Ate… 27900 (9780), n=3; Phase 2 - Coh. EXP-1 (EGFR-WT NSCLC) -… 19800 (9660), n=31; Phase 2 - Coh. EXP-2 (Gastric or GEJ Ad… 21500 (8620), n=11; Phase 2 - Coh. EXP-3 (Hepatocellular,He… 20500 (11400), n=7; Phase 2 - Coh. EXP-4 (EGFR Kinase Domai… 28600 (11900), n=15 [mean hours*microgram /milliLiter, Standard Deviation]
- Pharmacokinetics (PK) of AFM24
- Phase 1 - Cohort 1 - AFM24 160 mg + Ate… 3.15 (0.03), n=3; Phase 1 - Cohort 2 - AFM24 480 mg + Ate… 3.15 (0.13), n=4; Phase 2 - Coh. EXP-1 (EGFR-WT NSCLC) -… 9.78 (17.9), n=35; Phase 2 - Coh. EXP-2 (Gastric or GEJ Ad… 27.9 (24.5), n=11; Phase 2 - Coh. EXP-3 (Hepatocellular,He… 8.63 (15.8), n=8; Phase 2 - Coh. EXP-4 (EGFR Kinase Domai… 10.6 (17.4), n=20 [mean h, Standard Deviation]
- Frequency of Patients Developing Anti-drug Antibodies (ADAs) Against AFM24
- Phase 1 - Cohort 1 - AFM24 160 mg + Ate… 1/4; Phase 1 - Cohort 2 - AFM24 480 mg + Ate… 2/6; Phase 2 - Coh. EXP-1 (EGFR-WT NSCLC) -… 12/49; Phase 2 - Coh. EXP-2 (Gastric or GEJ Ad… 2/12; Phase 2 - Coh. EXP-3 (Hepatocellular,He… 3/11; Phase 2 - Coh. EXP-4 (EGFR Kinase Domai… 7/30 [Participants]
- ORR · Phase 1: Overall Response Rate (Complete Response [CR] or Partial Response [PR])
- Phase 1 - Cohort 1 - AFM24 160 mg + Ate… 1/3; Phase 1 - Cohort 2 - AFM24 480 mg + Ate… 0/6 [Participants]
Every value is copied from the trial’s results record at ClinicalTrials.gov. “Statistically significant” describes the posted test only: it does not say which group did better, and nothing here is read from a paper.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
AFM24-102 is a Phase 1/2a open-label, non-randomized, multicenter, dose escalation, and expansion study evaluating AFM24 in combination with atezolizumab in patients with selected EGRF-expressing advanced solid malignancies whose disease has progressed after treatment with previous anticancer therapies.
Detailed description public domain (ClinicalTrials.gov)
There will be 2 parts in this study: a dose escalation phase (phase 1) and an expansion phase (phase 2a). Patients will qualify to receive the investigational drugs (AFM24 + atezolizumab) in the dose escalation phase or the expansion phase only if they are deemed eligible following the safety lead-in phase. Seven days before the planned first combination treatment, patients will receive a single dose of AFM24 and will be observed for any adverse events for 1 week. The aim of the dose escalation phase is to determine the maximum tolerated dose (MTD)/recommended phase 2 dose (RP2D) of AFM24 in combination with atezolizumab. The dose escalation phase will be followed by the expansion phase once the MTD/RP2D of AFM24 in combination with atezolizumab has been determined. The expansion phase of the study is intended to collect preliminary evidence of efficacy and to further confirm the safety of AFM24 in combination with atezolizumab. The tumor types planned to be studied in the AFM24/atezolizumab combination study will be: * Non-small cell lung cancer (EGFR-WT), with disease progression after chemotherapy and PD1/PD-L1 targeted therapy * Gastric/GEJ cancer if intolerant to or with disease progression after standard platinum-based chemotherapy * Pancreatic/hepatocellular/biliary tract cancer with disease progression after standard of care (SOC) therapy or if there is no appropriate SOC available for their condition * Advanced or metastatic NSCLC harboring a targetable EGFR kinase domain mutation with disease progression on or after received ≥1 prior lines of treatment for advanced disease, including a Tyrosine-Kinase Inhibitor (TKI) for EGFR mutations
Posted results (ClinicalTrials.gov registry) · primary outcome public domain (ClinicalTrials.gov)
Phase 1: Incidence of Dose Limiting Toxicities (DLTs) During Cycle 1 [During cycle 1 (each cycle has 28 days)]. Count Of Participants, Participants. Phase 1 - Cohort 1 - AFM24 160 mg + Atezolizumab 840 mg (n=4): 0; Phase 1 - Cohort 2 - AFM24 480 mg + Atezolizumab 840 mg (n=6): 1.
Posted results (ClinicalTrials.gov registry) · primary outcome public domain (ClinicalTrials.gov)
Phase 2a: Overall Response Rate (Complete Response [CR] or Partial Response [PR]) [Tumor assessments were conducted during last week of cycle 2, 4, 6, 8, 10, 12 and every 3 cycles thereafter (each cycle has 28 days), up to approximately 97 weeks.]. Count Of Participants, Participants. Phase 2 - Coh. EXP-1 (EGFR-WT NSCLC) - AFM24 480 mg + Atezolizumab 840 mg (n=43): 8; Phase 2 - Coh. EXP-2 (Gastric or GEJ Adenocarcinoma) - AFM24 480 mg + Atezolizumab 840 mg (n=12): 1; Phase 2 - Coh. EXP-3 (Hepatocellular,Hepatobiliary,Pancreatic) - AFM24 480 mg + Atezolizumab 840 mg (n=11): 1; Phase 2 - Coh. EXP-4 (EGFR Kinase Domain Mutation NSCLC) - AFM24 480 mg + Atezolizumab 840 mg (n=28): 4.
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
Incidence of Patients With TEAEs [From first drug administration up to 30 (non-serious TEAEs) or 56 (serious TEAEs) days after last dose AFM24, until start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approx. 35 (phase 1) and 105 weeks (phase 2a).]. Count Of Participants, Participants. Phase 1 - Cohort 1 - AFM24 160 mg + Atezolizumab 840 mg (n=4): 4; Phase 1 - Cohort 2 - AFM24 480 mg + Atezolizumab 840 mg (n=6): 6; Phase 2 - Coh. EXP-1 (EGFR-WT NSCLC) - AFM24 480 mg + Atezolizumab 840 mg (n=49): 49; Phase 2 - Coh. EXP-2 (Gastric or GEJ Adenocarcinoma) - AFM24 480 mg + Atezolizumab 840 mg (n=12): 11; Phase 2 - Coh. EXP-3 (Hepatocellular,Hepatobiliary,Pancreatic) - AFM24 480 mg + Atezolizumab 840 mg (n=11): 11; Phase 2 - Coh. EXP-4 (EGFR Kinase Domain Mutation NSCLC) - AFM24 480 mg + Atezolizumab 840 mg (n=30): 30.
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
Incidence of Patients With SAEs [From first drug administration up to 56 days after the last dose of AFM24, until the start of a subsequent anticancer treatment, or data cut-off date, whichever is sooner. Up to approximately 35 (phase 1) and 105 weeks (phase 2a).]. Count Of Participants, Participants. Phase 1 - Cohort 1 - AFM24 160 mg + Atezolizumab 840 mg (n=4): 2; Phase 1 - Cohort 2 - AFM24 480 mg + Atezolizumab 840 mg (n=6): 3; Phase 2 - Coh. EXP-1 (EGFR-WT NSCLC) - AFM24 480 mg + Atezolizumab 840 mg (n=49): 30; Phase 2 - Coh. EXP-2 (Gastric or GEJ Adenocarcinoma) - AFM24 480 mg + Atezolizumab 840 mg (n=12): 6; Phase 2 - Coh. EXP-3 (Hepatocellular,Hepatobiliary,Pancreatic) - AFM24 480 mg + Atezolizumab 840 mg (n=11): 7; Phase 2 - Coh. EXP-4 (EGFR Kinase Domain Mutation NSCLC) - AFM24 480 mg + Atezolizumab 840 mg (n=30): 15.
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
Pharmacokinetics (PK) of AFM24 [During cycle 1 (each cycle has 28 days)]. Mean, ng/mL (Standard Deviation). Phase 1 - Cohort 1 - AFM24 160 mg + Atezolizumab 840 mg (n=3): 73700 (25400); Phase 1 - Cohort 2 - AFM24 480 mg + Atezolizumab 840 mg (n=4): 269000 (61400); Phase 2 - Coh. EXP-1 (EGFR-WT NSCLC) - AFM24 480 mg + Atezolizumab 840 mg (n=35): 207000 (78100); Phase 2 - Coh. EXP-2 (Gastric or GEJ Adenocarcinoma) - AFM24 480 mg + Atezolizumab 840 mg (n=11): 207000 (73400); Phase 2 - Coh. EXP-3 (Hepatocellular,Hepatobiliary,Pancreatic) - AFM24 480 mg + Atezolizumab 840 mg (n=8): 175000 (77200); Phase 2 - Coh. EXP-4 (EGFR Kinase Domain Mutation NSCLC) - AFM24 480 mg + Atezolizumab 840 mg (n=20): 250000 (106000).
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
Pharmacokinetics (PK) of AFM24 [During cycle 1 (each cycle has 28 days)]. Mean, ng/mL (Standard Deviation). Phase 1 - Cohort 1 - AFM24 160 mg + Atezolizumab 840 mg (n=3): 16700 (12500); Phase 1 - Cohort 2 - AFM24 480 mg + Atezolizumab 840 mg (n=4): 105000 (37200); Phase 2 - Coh. EXP-1 (EGFR-WT NSCLC) - AFM24 480 mg + Atezolizumab 840 mg (n=36): 56300 (48500); Phase 2 - Coh. EXP-2 (Gastric or GEJ Adenocarcinoma) - AFM24 480 mg + Atezolizumab 840 mg (n=12): 73700 (40900); Phase 2 - Coh. EXP-3 (Hepatocellular,Hepatobiliary,Pancreatic) - AFM24 480 mg + Atezolizumab 840 mg (n=7): 71900 (62500); Phase 2 - Coh. EXP-4 (EGFR Kinase Domain Mutation NSCLC) - AFM24 480 mg + Atezolizumab 840 mg (n=19): 93700 (51600).
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
Pharmacokinetics (PK) of AFM24 [During cycle 1 (each cycle has 28 days)]. Mean, hours*microgram /milliLiter (Standard Deviation). Phase 1 - Cohort 1 - AFM24 160 mg + Atezolizumab 840 mg (n=3): 5760 (919); Phase 1 - Cohort 2 - AFM24 480 mg + Atezolizumab 840 mg (n=3): 27900 (9780); Phase 2 - Coh. EXP-1 (EGFR-WT NSCLC) - AFM24 480 mg + Atezolizumab 840 mg (n=31): 19800 (9660); Phase 2 - Coh. EXP-2 (Gastric or GEJ Adenocarcinoma) - AFM24 480 mg + Atezolizumab 840 mg (n=11): 21500 (8620); Phase 2 - Coh. EXP-3 (Hepatocellular,Hepatobiliary,Pancreatic) - AFM24 480 mg + Atezolizumab 840 mg (n=7): 20500 (11400); Phase 2 - Coh. EXP-4 (EGFR Kinase Domain Mutation NSCLC) - AFM24 480 mg + Atezolizumab 840 mg (n=15): 28600 (11900).
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
Pharmacokinetics (PK) of AFM24 [During cycle 1 (each cycle has 28 days)]. Mean, h (Standard Deviation). Phase 1 - Cohort 1 - AFM24 160 mg + Atezolizumab 840 mg (n=3): 3.15 (0.03); Phase 1 - Cohort 2 - AFM24 480 mg + Atezolizumab 840 mg (n=4): 3.15 (0.13); Phase 2 - Coh. EXP-1 (EGFR-WT NSCLC) - AFM24 480 mg + Atezolizumab 840 mg (n=35): 9.78 (17.9); Phase 2 - Coh. EXP-2 (Gastric or GEJ Adenocarcinoma) - AFM24 480 mg + Atezolizumab 840 mg (n=11): 27.9 (24.5); Phase 2 - Coh. EXP-3 (Hepatocellular,Hepatobiliary,Pancreatic) - AFM24 480 mg + Atezolizumab 840 mg (n=8): 8.63 (15.8); Phase 2 - Coh. EXP-4 (EGFR Kinase Domain Mutation NSCLC) - AFM24 480 mg + Atezolizumab 840 mg (n=20): 10.6 (17.4).
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
Frequency of Patients Developing Anti-drug Antibodies (ADAs) Against AFM24 [Ph 1 within 2h prior to: each drug intake (Cycle 1), 1st + 3rd drug intake (Cycle 2 onwards) and at EOT, up to 27 weeks. Ph 2a within 2h prior to: 1st drug intake (Cycle 1 and Cycle 3 onwards), 1st + 3rd drug intake (Cycle 2) and at EOT, up to 97 weeks.]. Count Of Participants, Participants. Phase 1 - Cohort 1 - AFM24 160 mg + Atezolizumab 840 mg (n=4): 1; Phase 1 - Cohort 2 - AFM24 480 mg + Atezolizumab 840 mg (n=6): 2; Phase 2 - Coh. EXP-1 (EGFR-WT NSCLC) - AFM24 480 mg + Atezolizumab 840 mg (n=49): 12; Phase 2 - Coh. EXP-2 (Gastric or GEJ Adenocarcinoma) - AFM24 480 mg + Atezolizumab 840 mg (n=12): 2; Phase 2 - Coh. EXP-3 (Hepatocellular,Hepatobiliary,Pancreatic) - AFM24 480 mg + Atezolizumab 840 mg (n=11): 3; Phase 2 - Coh. EXP-4 (EGFR Kinase Domain Mutation NSCLC) - AFM24 480 mg + Atezolizumab 840 mg (n=30): 7.
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
Phase 1: Overall Response Rate (Complete Response [CR] or Partial Response [PR]) [Tumor assessments were conducted during last week of cycle 2, 4, 6, 8, 10, 12 and every 3 cycles thereafter (each cycle has 28 days), up to approximately 27 weeks.]. Count Of Participants, Participants. Phase 1 - Cohort 1 - AFM24 160 mg + Atezolizumab 840 mg (n=3): 1; Phase 1 - Cohort 2 - AFM24 480 mg + Atezolizumab 840 mg (n=6): 0.
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
Phase 2a: Progression-free Survival [From the first treatment received until the first progression disease assessed by investigator or death.]. Median, Months (95% Confidence Interval). Phase 2 - Coh. EXP-1 (EGFR-WT NSCLC) - AFM24 480 mg + Atezolizumab 840 mg (n=43): 3.75 (1.91 to 5.85); Phase 2 - Coh. EXP-2 (Gastric or GEJ Adenocarcinoma) - AFM24 480 mg + Atezolizumab 840 mg (n=12): 1.94 (1.48 to 8.71); Phase 2 - Coh. EXP-3 (Hepatocellular,Hepatobiliary,Pancreatic) - AFM24 480 mg + Atezolizumab 840 mg (n=11): 1.91 (0.99 to 2.53); Phase 2 - Coh. EXP-4 (EGFR Kinase Domain Mutation NSCLC) - AFM24 480 mg + Atezolizumab 840 mg (n=28): 3.71 (1.87 to 7.46).
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
Phase 2a: Duration of Response [From the date of first response (unconfirmed) until progression disease assessed by investigator or death.]. Median, Months (95% Confidence Interval). Phase 2 - Coh. EXP-1 (EGFR-WT NSCLC) - AFM24 480 mg + Atezolizumab 840 mg (n=8): 9.20 (3.71 to NA) [Not enough events to calculate the data.]; Phase 2 - Coh. EXP-2 (Gastric or GEJ Adenocarcinoma) - AFM24 480 mg + Atezolizumab 840 mg (n=1): NA (NA to NA) [Not enough events to calculate the data.]; Phase 2 - Coh. EXP-3 (Hepatocellular,Hepatobiliary,Pancreatic) - AFM24 480 mg + Atezolizumab 840 mg (n=1): 3.71 (NA to NA) [Not enough events to calculate the data.]; Phase 2 - Coh. EXP-4 (EGFR Kinase Domain Mutation NSCLC) - AFM24 480 mg + Atezolizumab 840 mg (n=4): 11.07 (6.54 to NA) [Not enough events to calculate the data.].
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
Phase 2a: Clinical Benefit Rate (CR or PR [Any Duration] or Stable Disease Equal or > 24 Weeks) [Tumor assessments were conducted during last week of cycle 2, 4, 6, 8, 10, 12 and every 3 cycles thereafter (each cycle has 28 days), up to approximately 97 weeks.]. Count Of Participants, Participants. Phase 2 - Coh. EXP-1 (EGFR-WT NSCLC) - AFM24 480 mg + Atezolizumab 840 mg (n=43): 11; Phase 2 - Coh. EXP-2 (Gastric or GEJ Adenocarcinoma) - AFM24 480 mg + Atezolizumab 840 mg (n=12): 2; Phase 2 - Coh. EXP-3 (Hepatocellular,Hepatobiliary,Pancreatic) - AFM24 480 mg + Atezolizumab 840 mg (n=11): 1; Phase 2 - Coh. EXP-4 (EGFR Kinase Domain Mutation NSCLC) - AFM24 480 mg + Atezolizumab 840 mg (n=28): 8.
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
Phase 2a: Disease Control Rate (DCR) (Complete Response [CR] or Partial Response [PR] or Stable Disease [SD]) [Tumor assessments were conducted during last week of cycle 2, 4, 6, 8, 10, 12 and every 3 cycles thereafter (each cycle has 28 days), up to approximately 97 weeks.]. Count Of Participants, Participants. Phase 2 - Coh. EXP-1 (EGFR-WT NSCLC) - AFM24 480 mg + Atezolizumab 840 mg (n=43): 27; Phase 2 - Coh. EXP-2 (Gastric or GEJ Adenocarcinoma) - AFM24 480 mg + Atezolizumab 840 mg (n=12): 5; Phase 2 - Coh. EXP-3 (Hepatocellular,Hepatobiliary,Pancreatic) - AFM24 480 mg + Atezolizumab 840 mg (n=11): 2; Phase 2 - Coh. EXP-4 (EGFR Kinase Domain Mutation NSCLC) - AFM24 480 mg + Atezolizumab 840 mg (n=28): 14.